Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Alona Zer(Rambam Health Care Campus), Natasha B. Leighl(Princess Margaret Cancer Centre), Paula A. Ugalde(Brigham and Women's Hospital), T. Mitsudomi(Izumi City General Hospital), Céline Mascaux(Hôpitaux Universitaires de Strasbourg), Myung‐Ju Ahn(Sungkyunkwan University), Pasi A. Jänne(Harvard University), L. Bubendorf(University Hospital of Basel), Pilar Garrido(Hospital Universitario Ramón y Cajal), Solange Peters(University Hospital of Lausanne), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Suresh Senan(Amsterdam Neuroscience), Fabrice Barlési(Hôpital Nord), Keith M. Kerr(University of Aberdeen), Lizza Hendriks(Maastricht University), Dirk De Ruysscher(Maastricht University Medical Centre), A. Sacher(University of Toronto)
Cited by 74
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k